Medtronic PLC (MDT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $131.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medtronic PLC (MDT) Stock Forecast
Analysts expect Medtronic (MDT) to earn $5.98 per share in the fiscal year ending Apr 30, 2027, on revenue of $38.97B. Of 30 analysts, 20 rate the stock Buy or Strong Buy, 10 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Apr 30, 2027 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 30 ratings average 2.23, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 10.0% |
| Buy | 17 | 56.7% |
| Hold | 10 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 30
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 7.2% and revenue estimates rise 3.7%.
- Fiscal year ending Apr 30, 2027
- $5.98
- EPS consensus, revenue $38.97B
- Fiscal year ending Apr 30, 2028
- $6.41
- EPS consensus, revenue $40.40B
- Next report
- Nov 24, 2026
- Confirmed, before the open
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Apr 30, 2027 | $5.98 | $5.93 to $6.02 | 30 | $38.97B | $37.51B to $39.19B | 28 |
| Apr 30, 2028 | $6.41 | $6.24 to $6.63 | 30 | $40.40B | $36.87B to $41.70B | 28 |
Quarterly Estimates
The EPS consensus rises from $1.42 for the quarter ending Jan 31, 2027 to $1.79 for the quarter ending Apr 30, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Jan 31, 2027 | $1.42 | $1.40 to $1.48 | 24 | $9.52B | $9.46B to $9.70B | 23 |
| Apr 30, 2027 | $1.79 | $1.67 to $1.90 | 26 | $10.40B | $10.02B to $10.88B | 25 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Apr 30, 2027 | 2 | 2 |
| Fiscal year ending Apr 30, 2028 | 4 | 1 |
| Quarter ending Jan 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Apr 30, 2027 has risen 0.5% from $5.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Apr 30, 2027 | $5.98 | $5.98 | $5.98 | $5.97 | $5.95 | +0.4% |
| Fiscal year ending Apr 30, 2028 | $6.41 | $6.41 | $6.41 | $6.40 | $6.41 | -0.1% |
| Quarter ending Jan 31, 2027 | $1.42 | $1.42 | $1.42 | $1.42 | $1.43 | -0.5% |
Frequently Asked Questions About MDT
What is the MDT stock forecast?
Consensus analyst estimates put Medtronic's EPS at $5.98 for the fiscal year ending Apr 30, 2027, on revenue of $38.97B. The consensus rating from 30 analysts is Buy.
How do analysts rate MDT stock?
Of 30 analysts covering Medtronic, 3 rate it Strong Buy, 17 Buy, 10 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from MDT next year?
For the fiscal year ending Apr 30, 2027, the consensus EPS estimate is $5.98, with estimates from $5.93 to $6.02 from 30 analysts. For the fiscal year ending Apr 30, 2028, the consensus EPS estimate is $6.41, with estimates from $6.24 to $6.63 from 30 analysts.
What revenue do analysts expect from Medtronic next year?
For the fiscal year ending Apr 30, 2027, the consensus revenue estimate is $38.97B, with estimates from $37.51B to $39.19B. For the fiscal year ending Apr 30, 2028, the consensus revenue estimate is $40.40B, with estimates from $36.87B to $41.70B.
How many analysts cover MDT?
30 analysts rate Medtronic stock, and 30 analysts estimate its EPS for the fiscal year ending Apr 30, 2027.
MDT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts